Suggested remit - To evaluate the benefits and costs of OTL-101 within its marketing authorisation for treating adenosine deaminase deficiency–severe combined immunodeficiency caused by for national commissioning by NHS England.
As no further information has been received from the company the topic has been discontinued.
- Status:
- Discontinued
- Decision:
- Prioritised
- Process:
- HST
- ID number:
- 1152
Project Team
- Project lead
- Michelle Adhemar
Email enquiries
If you have any queries please email scopingta@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 18 February 2026 | Discontinued. As no further information has been received from the company the topic has been discontinued. |
| 27 July 2018 - 24 August 2018 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
| 22 August 2018 | Note added to the project documents |
For further information on our processes and methods, please see our CHTE processes and methods manual